Loading…
Aclaris Therapeutics, Inc. is projected to rise to $6.40 by 2027, a +23% move from its current price of $5.20. ACRS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $5.07 | $5.21 | $5.35 | +0.10% |
| Aug 3 | $5.02 | $5.21 | $5.41 | +0.19% |
| Aug 4 | $4.98 | $5.22 | $5.46 | +0.29% |
| Aug 5 | $4.95 | $5.22 | $5.51 | +0.39% |
| Aug 6 | $4.92 | $5.23 | $5.55 | +0.49% |
| Aug 7 | $4.90 | $5.23 | $5.58 | +0.58% |
| Aug 8 | $4.88 | $5.24 | $5.62 | +0.68% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.88 | $5.24 | $5.62 | +0.68% |
| Week 2 | $4.77 | $5.27 | $5.83 | +1.37% |
| Week 3 | $4.69 | $5.31 | $6.00 | +2.06% |
| Week 4 | $4.64 | $5.34 | $6.16 | +2.75% |
| Week 5 | $4.59 | $5.38 | $6.30 | +3.45% |
| Week 6 | $4.55 | $5.42 | $6.44 | +4.16% |
| Week 7 | $4.52 | $5.45 | $6.58 | +4.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States.
Its product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
ACRS is a Healthcare stock trading under the symbol ACRS. The current price is $5.23 and the market cap is $730.44M. It ranks 2588.
For 2026 the average price is $5.23 with a min of $2.62 and a max of $7.10, and sentiment is NEUTRAL.
Looking further out, the forecast shows bullish sentiment with rising averages: 2027 avg $6.58, 2028 avg $7.81, 2029 avg $10.07, 2030 avg $12.91, 2040 avg $43.07, and 2050 avg $112.22. Max values reach $18.64 in 2030, $72.03 in 2040, and $204.96 in 2050, with ROIs of 146.8%, 723.6%, and 2045.7% respectively.
A major floor 36.5% below — a decisive break under it would weaken the trend.
The nearest floor, 13.5% below — buyers have tended to step in here.
The nearest ceiling, 9.8% above — a clean break opens room to run.
A major ceiling 22.1% above — clearing it would confirm fresh momentum.
Key ACRS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACRS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.27 | Sell | $5.27 | Sell |
| MA 10 | $5.39 | Sell | $5.34 | Sell |
| MA 20 | $5.47 | Sell | $5.33 | Sell |
| MA 50 | $4.97 | Buy | $5.05 | Buy |
| MA 100 | $4.55 | Buy | $4.60 | Buy |
| MA 200 | $3.74 | Buy | $3.93 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.11 | Neutral |
| Stoch RSI (14) | 11.87 | Buy |
| CCI (20) | -128.44 | Sell |
| Williams %R (14) | -85.96 | Info |
| MACD (12,26,9) | -0.08 | Sell |
| ROC (12) | -7.14 | Sell |
| Bollinger %B (20,2) | 0.09 | Neutral |
| Stochastic %K (14) | 14.04 | Buy |
| TRIX (15) | 0.44 | Buy |
| Awesome (5,34) | 0.06 | Buy |
| Ultimate (7,14,28) | 37.80 | Neutral |
| Momentum (10) | -0.48 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 5.17 | Buy |
| ADX (14) | 16.39 | Neutral |
| ATR (14) | 0.15 | Info |
The 30-day technical picture is BULLISH overall.
RSI14 is 60. SMA50 is $4.90 and SMA200 is $3.64. Support is at $4.10 and resistance at $5.71.
The 30-day range spans from $4.39 to $6.23, and annualized volatility is 50%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.62 | $5.20 | $6.99 | 0% | Neutral | |
| $5.11 | $6.40 | $8.46 | +23% | Bullish | |
| $5.91 | $7.60 | $10.43 | +46% | Bullish | |
| $7.25 | $9.54 | $13.47 | +83% | Bullish | |
| $9.09 | $12.21 | $17.66 | +135% | Bullish | |
| $10.93 | $14.94 | $22.07 | +187% | Bullish | |
| $11.89 | $16.54 | $24.89 | +218% | Bullish | |
| $13.10 | $18.52 | $28.35 | +256% | Bullish | |
| $14.26 | $20.46 | $31.83 | +293% | Bullish | |
| $14.49 | $21.09 | $33.28 | +306% | Bullish | |
| $25.50 | $39.62 | $66.46 | +662% | Bullish | |
| $58.13 | $101.02 | $185.20 | +18.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.62 | $5.20 | $6.28 | +0.00% |
| September 2026 | $4.60 | $5.44 | $6.62 | +4.68% |
| October 2026 | $4.77 | $5.68 | $6.98 | +4.36% |
| November 2026 | $4.72 | $5.65 | $7.00 | -0.48% |
| December 2026 | $4.66 | $5.60 | $6.99 | -0.91% |
Click any year to see its month-by-month ACRS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Aclaris Therapeutics, Inc.'s 2026 outlook centres on $5.20, within a $2.62 to $6.99 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ACRS could reach as high as $8.46, with a base case around $6.40 and support toward $5.11 — roughly +23% from $5.20. Buyers look set to stay in control over this stretch.
Expect ACRS to range from $5.91 to $10.43 through 2028. The $7.60 average target implies a +46% move from current prices. That is up +19% on the projected 2027 average. Momentum favours further upside here.
The ACRS price prediction for 2029 points to an average of $9.54 (low $7.25, high $13.47) — a potential gain of +83% on today's $5.20. Buyers look set to stay in control over this stretch.
In 2030, ACRS is projected to trade between $9.09 and $17.66, averaging $12.21 — a potential gain of +135% from today's $5.20. That is up +28% on the projected 2029 average. Momentum favours further upside here.
Aclaris Therapeutics, Inc.'s 2031 outlook centres on $14.94, within a $10.93 to $22.07 range. That is up +22% on the projected 2030 average. That marks a +187% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ACRS could reach as high as $24.89, with a base case around $16.54 and support toward $11.89 — roughly +218% from $5.20. Momentum favours further upside here.
Expect ACRS to range from $13.10 to $28.35 through 2033. The $18.52 average target implies a +256% move from current prices. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ACRS price prediction for 2034 points to an average of $20.46 (low $14.26, high $31.83) — a potential gain of +293% on today's $5.20. Momentum favours further upside here.
In 2035, ACRS is projected to trade between $14.49 and $33.28, averaging $21.09 — a potential gain of +306% from today's $5.20. That is up +3% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Aclaris Therapeutics, Inc.'s 2040 outlook centres on $39.62, within a $25.50 to $66.46 range. That is up +88% on the projected 2035 average. That marks a +662% change versus current levels. Momentum favours further upside here.
By 2050, ACRS could reach as high as $185.20, with a base case around $101.02 and support toward $58.13 — roughly +18.4x from $5.20. Buyers look set to stay in control over this stretch.
Investing $1,000 in ACRS today (≈ 192.307692 ACRS) could be worth
$19,426.09
+$18,426.09 (+1843%) by 2050 · US Dollar
Based on the average projected ACRS price of $101.02 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACRSwould be worth at today's price.
$1,000 invested in ACRS on Jul 31, 2025 (≈ 653.594783 ACRS) would be worth
$3,398.69
+$2,398.69 (+239.9%) today · 3.40× · US Dollar
Based on a ACRS entry price of $1.53 vs. today's $5.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.23 | $994.26 | -0.6% |
| 1 month ago | $5.34 | $973.78 | -2.6% |
| 3 months ago | $4.41 | $1,179.14 | +17.9% |
| 6 months ago | $3.61 | $1,440.44 | +44.0% |
| 1 year ago | $1.53 | $3,398.69 | +239.9% |
| All time (5.0y) ago | $15.08 | $344.83 | -65.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACRS forecast.
Our base-case forecast reaches $10.00 around 2030.
Implied market cap at $10.00: $1.4B
The multi-year forecast depicts a strong longer-term upside for the stock. In 2026 the min is $2.62, the avg is $5.23, the max is $7.10, with a neutral sentiment.
In 2027 the avg is $6.58 and the max is $8.70, with ROI 25.9 and sentiment BULLISH.
In 2028 the min is $6.07, the avg is $7.81, the max is $10.70, with ROI 49.3 and sentiment BULLISH.
In 2029 the min is $7.66, the avg is $10.07, the max is $14.19, with ROI 92.5 and sentiment BULLISH. In 2030 the min is $9.63, the avg is $12.91, the max is $18.64, with ROI 146.8 and sentiment BULLISH.
In 2031 the min is $11.45, the avg is $15.64, the max is $23.05, with ROI 198.9 and sentiment BULLISH. In 2032 the min is $12.71, the avg is $17.64, the max is $26.50, with ROI 237.3 and sentiment BULLISH. In 2033 the min is $14.00, the avg is $19.74, the max is $30.15, with ROI 277.4 and sentiment BULLISH.
In 2034 the min is $15.14, the avg is $21.68, the max is $33.63, with ROI 314.4 and sentiment BULLISH. In 2035 the min is $15.81, the avg is $22.95, the max is $36.13, with ROI 338.8 and sentiment BULLISH.
For 2040 the min is $27.82, the avg is $43.07, the max is $72.03, with ROI 723.6 and sentiment BULLISH. For 2050 the min is $64.91, the avg is $112.22, the max is $204.96, with ROI 2045.7 and sentiment BULLISH.
Tap a question to reveal the answer.
The forecast for 2030 shows min $9.63, avg $12.91, max $18.64, ROI 146.8, sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward, with 2027 avg $6.58 and ROI 25.9%, 2028 ROI 49.3%, 2029 ROI 92.5%, and continued upside through 2050; these are estimates, not guarantees.
Yes. The 2050 max is $204.96 and the 2050 avg is $112.22, so it could exceed $100.
Current price is $5.23 and market cap is $730.44M.
The long-term forecast shows bullish sentiment with rising averages: 2030 avg $12.91, 2040 avg $43.07, and 2050 avg $112.22; max values up to $18.64, $72.03, and $204.96; ROIs of 146.8%, 723.6%, and 2045.7%.
Aclaris Therapeutics, Inc. Community Discussion
0Share your Aclaris Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.